Glucose Modifies the Effect of Endovascular Thrombectomy in Patients With Acute Stroke A Pooled-Data Meta-Analysis

Ángel Chamorro, Scott Brown, Sergio Amaro, Michael D. Hill, Keith W. Muir, Diederik W.J. Dippel, Wim van Zwam, Ken Butcher, Gary A. Ford, Heleen M. den Hertog, Peter J. Mitchell, Andrew M. Demchuk, Charles B.L.M. Majoie, Serge Bracard, Igor Sibon, Ashutosh P. Jadhav, Blanca Lara-Rodriguez, Aad van der Lugt, Elizabeth Osei, Arturo Renú, Sébastien Richard, David Rodriguez-Luna, Geoffrey A Donnan, Anand Dixit, Mohammed Almekhlafi, Sandrine Deltour, Jonathan Epstein, Benoit Guillon, Serge Bakchine, Meritxell Gomis, Richard du Mesnil de Rochemont, Demetrius Lopes, Vivek Reddy, Gernot Rudel, Yvo B.W. E.M. Roos, Alain Bonafe, Hans-Christoph Diener, Olvert A. Berkhemer, Geoffrey C. Cloud, Stephen M. Davis, Robert van Oostenbrugge, Francis Guillemin, Mayank Goyal, Bruce C.V. Campbell, Bijoy K. Menon,
Stroke. 2019-03-01; 50(3): 690-696
DOI: 10.1161/STROKEAHA.118.023769


Lire sur PubMed

---

Background and Purpose—
Hyperglycemia is a negative prognostic factor after acute ischemic stroke but is not known whether glucose is associated with the effects of endovascular thrombectomy (EVT) in patients with large-vessel stroke. In a pooled-data meta-analysis, we analyzed whether serum glucose is a treatment modifier of the efficacy of EVT in acute stroke.

Methods—
Seven randomized trials compared EVT with standard care between 2010 and 2017 (HERMES Collaboration [highly effective reperfusion using multiple endovascular devices]). One thousand seven hundred and sixty-four patients with large-vessel stroke were allocated to EVT (n=871) or standard care (n=893). Measurements included blood glucose on admission and functional outcome (modified Rankin Scale range, 0–6; lower scores indicating less disability) at 3 months. The primary analysis evaluated whether glucose modified the effect of EVT over standard care on functional outcome, using ordinal logistic regression to test the interaction between treatment and glucose level.

Results—

Median (interquartile range) serum glucose on admission was 120 (104–140) mg/dL (6.6 mmol/L [5.7–7.7] mmol/L). EVT was better than standard care in the overall pooled-data analysis adjusted common odds ratio (acOR), 2.00 (95% CI, 1.69–2.38); however, lower glucose levels were associated with greater effects of EVT over standard care. The interaction was nonlinear such that significant interactions were found in subgroups of patients split at glucose < or >90 mg/dL (5.0 mmol/L;
P
=0.019 for interaction; acOR, 3.81; 95% CI, 1.73–8.41 for patients < 90 mg/dL versus 1.83; 95% CI, 1.53–2.19 for patients >90 mg/dL), and glucose < or >100 mg/dL (5.5 mmol/L;
P
=0.004 for interaction; acOR, 3.17; 95% CI, 2.04–4.93 versus acOR, 1.72; 95% CI, 1.42–2.08) but not between subgroups above these levels of glucose.

Conclusions—
EVT improved stroke outcomes compared with standard treatment regardless of glucose levels, but the treatment effects were larger at lower glucose levels, with significant interaction effects persisting up to 90 to 100 mg/dL (5.0–5.5 mmol/L). Whether tight control of glucose improves the efficacy of EVT after large-vessel stroke warrants appropriate testing.

Auteurs Bordeaux Neurocampus